ImmunoCellular Therapeutics Ltd (NYSEAMERICAN:IMUC) was the recipient of a large increase in short interest in January. As of January 31st, there was short interest totalling 2,403,971 shares, an increase of 6.3% from the January 12th total of 2,260,706 shares. Based on an average daily trading volume, of 1,251,998 shares, the days-to-cover ratio is presently 1.9 days. Approximately 6.8% of the company’s shares are short sold.

ImmunoCellular Therapeutics (IMUC) opened at $0.26 on Wednesday. ImmunoCellular Therapeutics has a 1-year low of $0.03 and a 1-year high of $3.68. The stock has a market capitalization of $5.23, a price-to-earnings ratio of -0.09 and a beta of 0.77.

ImmunoCellular Therapeutics (NYSEAMERICAN:IMUC) last posted its quarterly earnings data on Tuesday, November 21st. The biotechnology company reported ($0.40) earnings per share (EPS) for the quarter.

COPYRIGHT VIOLATION NOTICE: “ImmunoCellular Therapeutics Ltd (IMUC) Short Interest Update” was reported by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are reading this story on another website, it was illegally stolen and republished in violation of US and international trademark & copyright laws. The correct version of this story can be read at https://theolympiareport.com/2018/02/14/immunocellular-therapeutics-ltd-imuc-short-interest-update.html.

About ImmunoCellular Therapeutics

ImmunoCellular Therapeutics, Ltd. is a clinical-stage biotechnology company. The Company is developing immune-based therapies for the treatment of cancers. The Company’s cancer immunotherapies target cancer stem cells (CSCs), which are the drivers of tumor growth and disease recurrence. Its product candidate is ICT-107, which is in phase III testing.

Receive News & Ratings for ImmunoCellular Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmunoCellular Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.